Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) has been approved by the European Commission (EC).

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Vertex Pharmaceuticals Incorporated remains a top Buy with a strong cystic fibrosis franchise, innovative pipeline, and cell therapies. Click for my VRTX update.

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Vertex’s fifth CFTR modulator therapy, Alyftrek (vanza triple), is a next-in-class triple combination regimen that was approved by the FDA in December 2024 for treating people with CF aged six ...

ALYFTREK is currently licensed in the U.S., the UK and the European Union and is under regulatory review in Canada, Switzerland, Australia and New Zealand. About Vertex ...